

FOR IMMEDIATE RELEASE

Contact: Vartan Ghazarossian, Ph.D.
President and CEO
FlowMedica, Inc.
(510) 252-9500
info@FlowMedica.com

FLOWMEDICA RECEIVES 510(k) CLEARANCE FROM FDA FOR ITS BIFURCATED INFUSION SYSTEM

FREMONT, CA – February 19, 2004 – FlowMedica, Inc., a medical device company developing intravascular systems for facilitating the management of life-threatening renal conditions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its FlowMedica Bifurcated Infusion System. Cleared for infusion of physician-specified agents in the peripheral vasculature, the system is initially being evaluated for its ability to provide patients undergoing coronary interventional and diagnostic procedures with protection against kidney damage. This impaired function results from the use of potentially harmful radiocontrast agents, a condition known as radiocontrast nephropathy (RCN).

“This system addresses a large and unmet clinical need by protecting the kidneys during coronary procedures,” said Paul Teirstein, M.D., FACC, Director of Interventional Cardiology, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla. “It could be valuable in treating patients with renal failure who are in need of cardiovascular care.”

The FlowMedica Bifurcated Infusion System delivers therapeutic agents directly to the kidneys through a dedicated infusion catheter, allowing simultaneous coronary procedures and agent infusion through a single access site in the femoral artery. By delivering protective agents locally rather than systemically, the FlowMedica Bifurcated Infusion System is designed to increase the tolerable dose administered to the patient, thereby enhancing the agent’s effectiveness. The system consists of a proprietary Bifurcated Infusion Catheter and a unique Introducer Sheath.

About Radiocontrast Nephropathy

One of the most common causes of acute renal failure among hospitalized patients, RCN occurs when patients’ kidneys are unable to process the iodinated radiocontrast media administered during coronary interventional and diagnostic procedures. Consequently, kidney function is compromised and waste products build up in the bloodstream. RCN is associated with prolonged hospital stays, increased morbidity and mortality, and higher medical costs.

Worldwide, the number of contrast media-enhanced coronary examinations and interventions executed annually is large and rising; more than seven million procedures using iodinated radiocontrast media are performed each year. It is estimated that approximately one million patients worldwide undergoing these procedures are at risk of developing RCN each year.

About FlowMedica

FlowMedica is a venture-backed, privately held medical device company developing intravascular systems for facilitating the management of life-threatening renal conditions associated with cardiovascular disease, cancer, and surgery. The company's initial product is the FlowMedica Bifurcated Infusion System, a proprietary site-specific therapeutic agent infusion catheter system. Physicians are evaluating the system's ability to treat and prevent acute renal failure related to cardiovascular procedures, congestive heart failure, transplantation, and surgery, as well as facilitate cancer treatment. Founded in 2002 by Accelerated Technologies, Inc., FlowMedica has raised a total of \$8.5 million to date in venture capital funding from Medica Venture Partners, Medical Imaging Innovation & Investments, L.P., and Oxford Bioscience Partners.

###